20685 Background: Hand-foot syndrome (HFS), also known as hand-foot skin reaction, palmar-plantar erythrodysesthesia, toxic erythema of the palms and soles, is an acute-onset symptom complex affecting the palms of the hands and soles of the feet, affecting up to 42% of patients treated with systemic chemotherapy agents. HFS has also been seen with newer oral agents, including Nexavar (sorafenib) and Sutent (sunitinib malate). With growth in use of oral antineoplastic agents, dose escalation studies and the use of combination regimens, it is important to understand the depth and breadth of patient reported symptoms and health-related quality of life impacts. If not recognized early and managed effectively, HFS can evolve from an initially mild cutaneous reaction to an extremely painful and debilitating condition with considerable impact on a patient’s quality of life. As an initial step in the development of an HFS symptom assessment and quality of life questionnaire (the HF-QoL), we conducted one of the first extensive reviews of the peer-reviewed medical literature to: 1) identify descriptors of concepts and experiences relevant to HFS, and 2) to describe the state of the science on HRQL with HFS. Methods: A search of the National Library of Medicine Gateway electronic database was conducted for articles in English, from 2000/01/01 to 2007/02/13. Two reviewers independently screened all titles and/or abstracts including quality of life and economic evaluations. The full manuscript of any study judged to be relevant by either and both reviewers was obtained and assessed for inclusion or exclusion based on criteria determined a priori. Results: In total, 267 titles and abstracts were screened for inclusion in the review. Full paper manuscripts of 61 citations were assessed and reviewed for inclusion. Results were compiled and summarized in table format to document the range of depth of data collected on HRQL with HFS. Conclusions: Of the scientific articles found that reported on HFS in the context of cancer treatment, none of these articles reported direct assessments of quality of life impact of HFS. Instead, the literature has been limited to describing and/or grading toxicity. HRQL assessments are needed to better document the impact of HFS. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer Bayer Bayer, Bayer/Onyx